CClinicalTrials.gg
CompletedNCT01592552Updated Nov 22, 2023

A Biospecimen and Clinical Data Study on Patients for Drug & Biomarker Discovery

An observational study in Alzheimer's Disease, Multiple Sclerosis and Parkinson's Disease, sponsored by Sanguine Biosciences. Completed at 1 site in United States. Open to participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-22.

Sponsored by Sanguine Biosciences · Observational

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years to 100 Years
Sex
All
01

Study summary

The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

Read the detailed description

Blood samples are collected in the comfort and safety of your home by a certified medical professional. We have mobile phlebotomists located in major metropolitan areas around the nation for your convenience.

02

Conditions studied

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)

Keywords

  • Alzheimer's Disease
  • Multiple Sclerosis
  • Parkinson's Disease
  • Huntington's Disease
  • Amyotrophic Lateral Sclerosis (ALS)
03

In context

Parkinson Disease

4,487 studies on the registry are indexed under Parkinson Disease; 1,082 are open to participants now.

This study's enrollment of 20 is below the median of 96 across 1,057 observational studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Sanguine Biosciences is the lead sponsor of 13 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

A diagnosis of Multiple Sclerosis, Alzheimer's, Huntington's, or Parkinson's Disease.

Inclusion criteria

  • Males and females >18 to 100 years old
  • A diagnosis of neurological condition
  • Proof of diagnosis can be provided

Control group: Healthy donors, males and females, 18 to 100 years of age

Exclusion criteria

Exclusion Criteria

  • Receipt of blood products within 30 days of study enrollment
  • Receipt of an investigational (unapproved) drug within 30 days of study enrollment
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
20 participants (actual)

Groups and cohorts

  • Neurological Condition

    Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

  • Control

    Collect blood and other biospecimens like saliva, urine and CSF for research purposes.

06

What researchers measure

Primary outcomes

  1. Biospecimens & Clinical Data collection from patients with neurological diseases.

    The purpose of this research project is to collect and store blood samples and clinical data. Researchers can then use the stored samples in future studies. Through such studies, they hope to find new ways to detect, treat, and maybe even prevent or cure health problems.

    Time frame: 2 years

07

Study locations

1 site
  • Sanguine Biosciences
    Sherman Oaks, California 91403, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01592552
Lead sponsor
Sanguine Biosciences
Responsible party
Sponsor
First posted
May 7, 2012
Start date
Nov 2011
Primary completion
Mar 2015
Completion
Mar 2015
Last update
Nov 22, 2023

Study contacts

Phil Silkoff, MD
principal investigator · Sanguine Biosciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion